A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura†
References (25)
Childhood acute idiopathic thrombocytopenic purpura: how many tests and how much treatment required?
J Pediatr
(1985)Treatment of acute idiopathic thrombocytopenic purpura [Letter]
J Pediatr
(1986)- et al.
Idiopathic thrombocytopenic purpura: an epidemiologic study
J Pediatr
(1973) - et al.
Idiopathic thrombocytopenic purpura in children
J Pediatr
(1975) - et al.
Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood
Lancet
(1985) - et al.
Treatment of acute idiopathic thrombocytopenia of childhood with intravenous infusions of gammaglobulin
J Pediatr
(1985) - et al.
Idiopathic thrombocytopenic purpura in childhood
Semin Thromb Hemost
(1977) Idiopathic (immune) thrombocytopenic purpura in children: pathogenesis and treatment
Pediatr Rev
(1983)Idiopathic thrombocytopenic purpura in children: diagnosis and management
Pediatrics
(1975)- et al.
Childhood idiopathic thrombocytopenic purpura: to treat or not to treat?
Am J Dis Child
(1977)
Idiopathic thrombocytopenic purpura—where do we stand?
Arch Dis Child
Treatment of acute idiopathic thrombocytopenic purpura [Letter]
J Pediatr
Cited by (237)
Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology
2021, Journal of Thrombosis and HaemostasisRole of immunoglobulin and antibodies in disease management
2021, International Journal of Biological MacromoleculesProtocol for the study and treatment of primary immune thrombocytopenia: PTI-2018
2019, Anales de PediatriaAmerican Society of Hematology 2019 guidelines for immune thrombocytopenia
2019, Blood AdvancesCitation Excerpt :There were no RCTs that reported data on mortality, major bleeding, or overall HRQoL. For the studies that reported only 1 arm of data, 9 studies reported on durable response (7 IVIG arm,108,109,123-126,130 2 anti-D immunoglobulin arm135,136), 1 study reported on remission (1 IVIG arm123), 3 studies reported on hemolysis (yes/no) (1 IVIG arm,126 2 anti-D immunoglobulin arm135,136), 2 studies reported on mortality (1 IVIG arm,123 1 anti-D immunoglobulin arm135), 5 studies reported on major bleeding (5 IVIG arm108,109,123,126,130), and 0 studies reported on overall HRQoL. The EtD framework is shown online at https://guidelines.gradepro.org/profile/8810F037-714A-05B5-A135-A20932FAC54F.
- †
Supported by a grant from the Physicians' Services Incorporated Foundation of Ontario, Canada.